Alexion Pharmaceuticals (ALXN) Revenue and Net Income History
Historical revenue, operating income and net income for Alexion Pharmaceuticals (ALXN) over the last 10 years. The current TTM revenue for Alexion Pharmaceuticals as of September 19, 2017 is $3.08B.
|Medical||Medical - Biomedical and Genetics||$32.058B||$3.084B|
|Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company's lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional.|